## CLAIMS

1. Use of natural human alpha interferon, ribavirin, a dsRNA, and optionally a neuraminidase inhibitor, for the manufacture of a medicament for the treatment in a human patient of avian influenza or a susceptible viral infection other than avian influenza which has a common mechanism of viral multiplication or pathogenesis, in whole or in part, similar to that of avian flu, wherein the natural human alpha-interferon consists of seven different alpha interferons $\alpha$-2, $\alpha$-4, $\alpha$-7, $\alpha$-8, $\alpha$-10, $\alpha$-16 and $\alpha$-17.

2. The use of claim 1, wherein infection of the patient by avian influenza strain H5N1 is treated.

3. The use of claim 1, wherein the dsRNA is $rI_n \cdot r(C_{12}U)_n$, Poly A · Poly U, or $rI_n \cdot r(C_{29}G)_n$, in which r is ribo.

4. The use of claim 1, wherein the dsRNA is Ampligen®.

5. The use of claim 1, wherein the interferon is Alferon®.

6. The use of claim 1, wherein the interferon is administered to the patient orally, nasally, intravenously, intramuscularly or subcutaneously in an amount of at least 3 IU per pound of the patient's body weight.

7. The use of claim 1, wherein the dsRNA is administered to the patient orally, nasally, intravenously, intramuscularly, or subcutaneously.

8. Use of natural human α-interferon in combination with ribavirin and a dsRNA for the manufacture of a medicament for mitigating the effects of or conferring resistance to avian influenza or a susceptible viral infection other than avian influenza which has a common mechanism of viral multiplication or pathogenesis, in whole or in part, similar to that of avian influenza in the treatment of a human patient prior to exposure to or shortly after exposure to the virus, but prior to the development of symptoms, wherein the natural human alpha-interferon consists of seven different alpha interferons α-2, α-4, α-7, α-8, α-10, α-16 and α-17.

9. The use of claim 8, wherein infection of the patient by avian influenza strain H5N1 is treated.

10. The use of claim 9, wherein the dsRNA is $rI_n \cdot r(C_{12}U)_n$, Poly A · Poly U, or $rI_n \cdot r(C_{29},G)_n$, in which r is ribo.

11. The use of claim 10, wherein the dsRNA is Ampligen®.

12. The use of claim 8 or 9, wherein the interferon is Alferon®.

13. The use of claim 8 or 9, wherein the interferon is administered to the patient orally, nasally, intravenously, intramuscularly or subcutaneously in an amount of at least 3 IU per pound of the patient's body weight.

14. The use of claim 9, wherein the dsRNA is administered to the patient orally, nasally, intravenously, intramuscularly, or subcutaneously.

## CLAIMS

1. Use of natural human alpha interferon, ribavirin, a dsRNA, and optionally a neuraminidase inhibitor, for the manufacture of a medicament for the treatment in a human patient of avian influenza or a susceptible viral infection other than avian influenza which has a common mechanism of viral multiplication or pathogenesis, in whole or in part, similar to that of avian flu, wherein the natural human alpha-interferon consists of seven different alpha interferons $\alpha$-2, $\alpha$-4, $\alpha$-7, $\alpha$-8, $\alpha$-10, $\alpha$-16 and $\alpha$-17, and wherein the dsRNA is rIn • r(C12U)n., Poly A • Poly U, or rIn • r(C29,G)n, in which r is ribo.

2. The use of claim 1, wherein infection of the patient by avian influenza strain H5N1 is treated.

3. The use of claim 1, wherein the dsRNA is Ampligen®.

4. The use of claim 1, wherein the interferon is Alferon®.

5. The use of claim 1, wherein the interferon is administered to the patient orally, nasally, intravenously, intramuscularly or subcutaneously in an amount of at least 3 IU per pound of the patient's body weight.

6. The use of claim 1, wherein the dsRNA is administered to the patient orally, nasally, intravenously, intramuscularly, or subcutaneously.

7. Use of natural human α-interferon in combination with ribavirin and a dsRNA for the manufacture of a medicament for mitigating the effects of or conferring resistance to avian influenza or a susceptible viral infection other than avian influenza which has a common mechanism of viral multiplication or pathogenesis, in whole or in part, similar to that of avian influenza in the treatment of a human patient prior to exposure to or shortly after exposure to the virus, but prior to the development of symptoms, wherein the natural human alpha-interferon consists of seven different alpha interferons α-2, α-4, α-7, α-8, α-10, α-16 and α-17.

8. The use of claim 7, wherein infection of the patient by avian influenza strain H5N1 is treated.

9. The use of claim 8, wherein the dsRNA is $rI_n \cdot r(C_{12}U)_n$, Poly A · Poly U, or $rI_n \cdot r(C_{29},G)_n$, in which r is ribo.

10. The use of claim 9, wherein the dsRNA is Ampligen®.

11. The use of claim 7 or 8, wherein the interferon is Alferon®..

12. The use of claim 7 or 8, wherein the interferon is administered to the patient orally, nasally, intravenously, intramuscularly or subcutaneously in an amount of at least 3 IU per pound of the patient's body weight.

13. The use of claim 8, wherein the dsRNA is administered to the patient orally, nasally, intravenously, intramuscularly, or subcutaneously.